Highest-materiality recent filing
Seres Therapeutics stockholders approve 900k share increase to 2025 Incentive Award Plan
Stockholders approved amendment to 2025 Incentive Award Plan, increasing shares available by 900,000.
Seres reports 80% immunosuppressive-free clinical response for SER-155 in irEC trial
12 of 15 patients (80%) achieved primary endpoint: ≥1-grade diarrhea improvement without immunosuppressives at Day 15.
Nestlé Health Science pays $25M in two $12.5M installments (July & Oct 2026) to buy out future VOWST sales milestones.
Seres Therapeutics board member Hans-Juergen Woerle resigns, effective May 31, 2026
Dr. Woerle resigned from the board and all committees, effective May 31, 2026.
Seres Q1 2026 net loss $19.9M; cash runway only through Q3 2026
Net loss $19.9M vs net income $32.7M in Q1 2025 (which included $50M Nestlé payment).
Seres Therapeutics sets 2026 annual meeting for June 9
Record date for voting is April 13, 2026; stockholders of record on that date are entitled to vote.
Full-year 2025 net income from continuing ops $5.7M vs net loss of $125.8M in 2024; Q4 net loss $15.3M.
Seres Therapeutics appoints Richard Kender as Interim CEO, effective March 2
Thomas DesRosier and Marella Thorell step down as co-Presidents/co-CEOs but remain EVP CLO and EVP CFO.
Net income from continuing ops $8.2M vs loss of $51.0M in Q3 2024, driven by $27.2M gain on VOWST sale.
Seres Therapeutics cuts workforce 25%, extends cash runway into Q2 2026
Reducing workforce by approximately 25%, including reductions effective August 2025.
Seres Q2 net loss narrows to $19.9M; CEO replaced; SER-155 Phase 2 protocol filed
Net loss from continuing ops $19.9M in Q2 2025 vs $26.2M in Q2 2024; cash $45.4M as of June 30.
Seres Therapeutics CEO Eric Shaff resigns; CFO and CLO appointed as Co-CEOs effective Aug 1, 2025
Eric Shaff resigns as President and CEO effective July 31, 2025; remains on Board as Class I director.
Seres Q1 net income $32.7M; SER-155 Phase 2 protocol to FDA in weeks
Net income from continuing ops of $32.7M vs net loss of $32.9M YoY, driven by $50M Nestlé installment.
Seres Therapeutics effects 1-for-20 reverse stock split, effective April 21, 2025
Reverse stock split at 1-for-20 ratio, effective 5:00 PM ET on April 21, 2025.
Seres Therapeutics stockholders approve 1-for-20 reverse stock split, 2025 Incentive Plan
Reverse stock split at 1-for-20 ratio approved; effective April 21, 2025; trading on split-adjusted basis April 22 under symbol MCRB.
Seres Q4 net loss from continuing ops $15.7M; cash extends into Q1 2026; SER-155 advances
Net loss from continuing ops: FY2024 $125.8M vs $190.1M in 2023; Q4 $15.7M vs $34.7M.
Seres Therapeutics CMO Lisa von Moltke resigns effective March 14, 2025
Lisa von Moltke, M.D., notified Seres of her resignation as EVP and Chief Medical Officer.
Seres Therapeutics appoints Hans-Juergen Woerle, M.D. to board, designated by Nestlé
Board expanded to nine directors; Woerle appointed as Class III director effective Feb 4, 2025.
Company posted updated corporate presentation on investor website ahead of J.P. Morgan Conference on January 16, 2025.
Seres reports $31M cash, SER-155 biomarker data positive, FDA Breakthrough Therapy
Prelim cash $31M as of Dec 31, 2024; with Nestlé payments of ~$75M, cash runway into Q1 2026.
Nasdaq notified Seres (MCRB) that bid price closed below $1.00 for 30 consecutive business days; must regain compliance by May 6, 2025.
Seres completes VOWST sale to Nestlé for ~$175M gross; debt retired, runway to Q4 2025
Received ~$175M gross at close: $100M upfront, $60M prepaid milestone, $15M equity; net ~$155M after ~$20M settlement.
Seres stockholders approve sale of VOWST business to Nestlé; close expected Sept 30
Stockholders voted 77.1M for, 7.1M against, and 0.2M abstain to approve the sale of VOWST business to Société des Produits Nestlé S.A.
Seres' SER-155 reduces BSIs 10% vs 42.9% in allo-HSCT Phase 1b; seeks Breakthrough Therapy
SER-155 cut bloodstream infections to 10% vs 42.9% placebo (p=0.0423) in 34 evaluable patients.
Seres files prior financials for proxy on VOWST asset sale; auditor flags going concern
Furnishes 2022-2023 audited financial statements for incorporation in proxy statement related to sale of VOWST microbiome assets.
Seres Q2 net loss $32.9M; VOWST sales $14.4M (+43% QoQ); announces $175M asset sale to Nestlé
Net loss $32.9M vs net income $46.6M in Q2 2023 (prior year included $125M VOWST milestone from Nestlé).
Seres sells VOWST to Nestlé Health Science for $175M upfront plus milestones
Seres to receive $175M at closing: $100M upfront (less ~$20M net settlement), $60M prepaid milestone, $15M equity at $1.05/share.
Seres sells VOWST business to Nestlé for up to $100M cash plus milestones; issues $15M stock
Cash payment of $100M at closing (net of ~$17.9M owed to Nestlé affiliate and ~CHF2M to Bacthera); $50M due Jan 2025, $25M July 2025.
Seres Q1 net loss $40.1M, VOWST sales $10.1M; SER-155 data expected Q3
Net loss $40.1M vs $71.2M YoY; VOWST net sales $10.1M (642 units).
Seres receives Oaktree default notice over $28M Bacthera payment; $110M term loan at risk
Received default notice from Oaktree alleging non-payment of ~$28M milestone to Bacthera; company disputes.
Seres Therapeutics receives Nasdaq delisting notice for bid price below $1.00
Received Nasdaq letter on April 19, 2024, for bid price closing below $1.00 for 30 consecutive business days.
Seres Therapeutics shareholders approve increase in authorized common shares from 240M to 360M
Amendment to certificate of incorporation filed April 5, 2024, increasing authorized shares from 240M to 360M.
Seres Therapeutics Q4/FY2023: VOWST net sales $10.4M Q4, $19.6M YTD; net loss narrows to $113.7M
Net loss of $113.7M for FY2023 versus $250.2M prior year; Q4 net loss $41.2M vs $68.8M.
Seres Therapeutics appoints Marella Thorell as CFO; David Arkowitz retires March 15
Marella Thorell named EVP and CFO effective March 25, 2024; David Arkowitz retires as CFO on March 15.
Seres Therapeutics sets 2024 annual meeting for April 4, 2024
Record date for voting is February 12, 2024; meeting will be held virtually.
Seres reports preliminary Q4 VOWST net sales of $10.4M; FDA Fast Track for SER-155
VOWST Q4 2023 net sales approx $10.4M (unaudited); total 2023 net sales since June launch approx $19.6M.
Company filed an 8-K on Jan 9, 2024 to disclose an updated corporate presentation.
Seres Therapeutics amends bylaws to adopt universal proxy rules and update nomination procedures
Amended bylaws require compliance with SEC Rule 14a-19 for non-Board director nominee solicitations.
Seres Q3 2023 VOWST sales $7.6M; cuts 41% workforce, targets $75-85M annual savings
Q3 net loss $47.9M vs $60.0M YoY; VOWST net sales $7.6M from 506 units in first full quarter.
Director Grégory Behar resigns from Seres Therapeutics board effective Oct 2, 2023
Grégory Behar resigned from the board effective October 2, 2023.
Seres reports Q2 2023 net income of $46.6M on $125M VOWST milestone; early launch demand strong
Net income $46.6M vs net loss $64.7M YoY; $125M milestone from Nestlé upon FDA approval of VOWST.
Seres increases authorized shares to 240M and updates on Oaktree credit facility tranche conditions
Stockholders approved increase in authorized common shares from 200M to 240M; Certificate of Amendment filed June 27, 2023.
Seres stockholders approve increase in authorized shares from 200M to 240M at annual meeting
All three Class II director nominees elected: Berenson, Kender, and Fraser.
VOWST (fecal microbiota spores) FDA-approved for recurrent C. difficile; launch expected June 2023.
FDA approved VOWST (fecal microbiota spores) to prevent recurrent C. difficile infection; launch expected June 2023.
Seres Therapeutics reports FY2022 net loss $250.2M, SER-109 PDUFA date April 26, 2023
FY2022 net loss $250.2M vs $65.6M in FY2021; Q4 net loss $68.8M vs $50.0M.
Filed updated corporate presentation as Exhibit 99.1 on January 9, 2023.
Seres Therapeutics appoints Claire Fraser, Ph.D. as Class II director and to Audit Committee
Board expanded to ten directors; Dr. Fraser appointed as Class II director and to Audit Committee.
Seres amends Cambridge lease: surrenders 14,760 sq ft, extends 68,636 sq ft to Jan 2030
Surrenders 14,760 rentable sq ft of office/lab space effective Nov 12, 2023.
Net loss of $60.0M in Q3 2022 vs net income of $68.2M in Q3 2021; R&D expenses $43.1M.
On May 30, 2026, Hans-Juergen Woerle, M.D., Ph.D. resigned from his position as a member of the board of directors of Seres Therapeutics, Inc. (the “Company”) and on the committees on which he serves, effective May 31, 2026.
On February 22, 2025, Lisa von Moltke, M.D. notified Seres Therapeutics, Inc. (the “Company”) of her intention to resign as the Executive Vice President and Chief Medical Officer of the Company, effective as of March 14, 2025.
appointed Hans-Juergen Woerle, M.D., as a Class III director of the Company, effective immediately.
Mr. Arkowitz’s retirement effective as of March 15, 2024 (the “Retirement Date”).
On February 24, 2024, the Board of Directors (the “Board”) of Seres Therapeutics, Inc. (the “Company”) appointed Marella Thorell to succeed David Arkowitz as the Company’s Executive Vice President and Chief Financial Officer, effective as of the commencement of her employment with the Company, which is expected to be on or about March 25, 2024 (the “Effective Date”), following Mr. Arkowitz’s retirement effective as of March 15, 2024 (the “Retirement Date”).
On October 2, 2023, Grégory Behar informed Seres Therapeutics, Inc. (the “Company”) of his resignation from the board of directors of the Company, effective immediately, in connection with his resignation from Nestlé Health Science.
On January 4, 2023, the Board of Directors (the “Board”) of Seres Therapeutics, Inc. (the “Company”) increased its size to provide for a total of ten directors authorized to serve on the Board and appointed Claire Fraser, Ph.D. as a Class II director of the Company.
Max materiality 0.95 · Median 0.70 · Most common event other_material